Endothelial cells participate in inflammatory events leading to atherogenesis by regulating endothelial cell permeability via the expression of VE-Cadherin and β-catenin and leukocyte recruitment via the expression of ESelectins and other adhesion molecules. The protein p66 
Introduction
Endothelial dysfunction plays a major role in the pathogenesis of vascular damage [1] . Typically, the functional impairment of the endothelium induced by metabolic factors and/or cytokines precedes the development of morphological alterations [1, 2] , and is documented at a biochemical level by the abnormal expression of endothelial cell-specific genes [3] . In vitro, exposure of human endothelial cells to the proinflammatory cytokine TNFα results in the activation of the NF-κB [4] and MAP kinase signaling pathways [5] , and expression of adhesion molecules and other mediators [6, 7] , which increase endothelial cell permeability [8] , locally recruit circulating leukocytes and promote diapedesis through the endothelial layer, thus initiating the atherosclerotic cascade [1] .
E-Selectin is a Ca 2+ -dependent cell surface glycoprotein that recruits leukocytes under proinflammatory conditions [8] , and is transcriptionally induced in response to inflammatory cytokines, such as IL-1β and TNFα [9] . Elevated cellular levels of ESelectin have been documented in various diseases associated with a pro-inflammatory condition, including diabetes, atherosclerosis, rheumatoid arthritis, and cancer [10] [11] [12] . Conversely, therapeutic strategies, which reduce vascular injury, result in significant down-regulation of ESelectin gene expression [13] [14] [15] .
Tight intercellular junctions connecting endothelial cells are required to prevent the vascular contents from leaking into surrounding tissue space [16] . The interaction between vascular endothelial(VE)-cadherin [17] , a type-II endothelialrestricted classical cadherin, and β-catenin [18] is critical for cell-cell adhesion and cytoskeleton anchoring [19] . Disruption of the adherent junctions at the level of VE-cadherin and β-catenin is an important mechanism leading to microvascular hyperpermeability [20] . Under inflammatory conditions, the increased permeability is associated with downregulation of VE-cadherin [21] . Enhanced endothelial cell permeability associated with increased β-catenin expression and disruption of the VE-cadherin/β-catenin complexes has been observed in human endothelial cells exposed to a proinflammatory milieu [22] . Thus, defining the mechanisms regulating E-Selectin expression, endothelial cell permeability and leukocyte transmigration may increase our understanding of the development of vascular damage and may potentially identify new therapeutic targets for cardiovascular disease.
The mammalian Shc locus encodes for three different ShcA adaptor proteins with respective M r of 46, 52, and 66 kDa. Phosphorylation of the 66-kDa isoform, p66
Shc , on Ser 36 has been associated with negative regulation of the p46/52 Shc complex, activation of oxidative stress, and increased cellular apoptosis [23] [24] [25] . Genetic deletion of p66
Shc in the mouse results in reduced systemic and cellular stress and increased lifespan [24] . In light of its pivotal role as a cellular stress sensor, several studies have investigated the pathophysiological contribution of p66
Shc to vascular damage and cardiovascular diseases. p66 Shc knockout mice are protected from high fat diet-induced atherosclerosis due to decreased oxidative stress and formation of foam cells [26, 27] , as well as from diabetes-induced endothelial dysfunction and diabetic glomerulopathy. Interestingly, p66
Shc protein levels appear to be increased in the aorta and renal cortex of experimental models of diabetes and in circulating leucocytes from diabetic patients [27, 28] . However, the mechanisms by which p66
Shc may promote atherogenesis are still largely unknown and the role of p66
Shc in cytokine-induced endothelial dysfunction has not been addressed.
In this study, we provide evidence that p66 Shc , through its Ser 36 phosphorylation, mediates TNFα-induced endothelial cell permeability by disrupting the cadherin-catenin complex and increases leukocyte transmigration through the HUVEC monolayer by increasing E-Selectin expression levels.
Materials and Methods

Cell cultures
HUVEC and HL-60 cells were purchased from ATCC (Manassas, VA). HUVEC were grown on six-well plates to confluence at 37°C in a humidified incubator gassed with 5% CO 2 , in F12 Kaighn's medium (GIBCO, Palo Alto, CA), supplemented with 10% Foetal Bovine Serum (GIBCO, Palo Alto, CA), 100 IU/ml penicillin, 100 µg/ml streptomycin (LONZA, MD, Iquique, Chile), non-essential amino acids (GIBCO Invitrogen, Paisley, UK), 25 mg/ml Endothelial Cell Growth Supplement (SIGMA-ALDRICH, St Louis, MO), and 0.1 mg/ml heparin (SIGMA-ALDRICH, St Louis, MO). HUVEC were treated with the JNK inhibitors SP600125 (30 µM for 2 h) (SIGMA, St Louis MO) or JNKi peptide [29] (10 mg/ml for 2 h), the MEK inhibitor PD98059 (30 μM or 50 μM for 2 h) (Calbiochem, La Jolla, CA), the p38 MAPK inhibitor SB203580 (15 μM or 30 μM for 1 h) (Calbiochem, La Jolla, CA), the PKC-β inhibitor LY333531 (200 nM for 1 h or 24 h) (R&D Systems, Abingdon, UK) or the antioxidant agent N-acetyl-cysteine (NAC, 10 mM for 2 h) (Sigma Aldrich, St. Louis, MO) before treatment with TNFα (R&D Systems, Abingdon, UK). The NADPH oxidase (Nox)-inhibitor 3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo [4,5-d] pyrimidine (VAS2810, 5 µM), and the complex I (NADH dehydrogenase) inhibitors rotenone (10 µM) and thenoyltrifluoroacetone (TTFA, 10 µM) (purchased from SIGMA-ALDRICH, St Louis, MO) were coincubated with TNFα for 0.5 h. The JNKi peptide sequence, 5(6)-FAM-GRKKRRQRRRPPRPKRPTTLNLFPQVPRSQDT-COOH, was synthetized by Primm (Milan, Italy) and linked to a FITC fluorochrome to visualize its cell entry and accumulation. The promyelocytic cell line HL-60 was cultured in Iscove's Modified Dulbecco's Medium (ATCC, Manassas, VA) with 100 IU/ml penicillin, 100 μg/ml streptomycin (LONZA, MD, Iquique, Chile), and 10% of FBS (GIBCO, Palo Alto, CA). Cell viability was assessed by trypan blue dye (SIGMA-ALDRICH, St Louis, MO) exclusion. Cell number was calculated using Scepter 
Adenoviral transfection studies
HUVEC expressing increased levels of the p66
Shc protein were obtained as described previously [30] . Briefly, the gene of interest was cloned into the shuttle vector pAdTrack-CMV, then co-transformed into E. coli BJ5183 cells with the adenoviral backbone plasmid pAdEasy-1, and transfected into the adenovirus packaging cell line QBI293A. Scalar doses of adenovirus-containing culture medium were used to biologically define the optimal HUVEC infection dose (>90% of infected cells). To obtain HUVEC overexpressing a dominant-negative p66
Shc mutant, cells were transfected with an adenoviral construct carrying a Ser 36 to Ala 36 mutation. An empty adenovirus was used as control for the infection (mock).
siRNA transfection studies
Two independent siRNAs were used to obtain a selective reduction of p66
Shc mRNA and protein expression: siRNA#1 (5'-AUGAGUCUCUGUCAUCGCUTT-3'; 5'-AGCGAUGACAGAGACUCAUTC-3') [31] , and siRNA#2 (5'-UGAGUCUCUGUCAUCGCUGTT-3'; 5'-CAGCGAUGACAGAGACUCATT-3'. Both siRNA were designed using the siRNA Target Finder software and synthesized by Qiagen (Hilden, Germany). Two independent siRNAs were used to obtain a selective reduction of E-Selectin expression: siRNA#1 [32] was synthesized by Qiagen and siRNA#2 [33] was purchased by Santa Cruz Biotechnology Inc.
(sc-29296, Santa Cruz, CA). Control, non-silencing fluorescently labeled siRNA was obtained from Qiagen (AllStars Negative Control siRNA, Hilden, Germany). Cell transfection was achieved using Lipofectamine™ (Invitrogen, Carlsbad, CA), according to the manufacturer's instructions. Selective reduction of p66
Shc gene and protein expression was verified by real-time RT-PCR (qPCR) two and three days following transfection, respectively.
Immunoblotting
Cells were lysed in 50 mM HEPES, pH 7.5, containing 150 mM NaCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 4 mM EDTA, 1% Triton X-100, 10% glycerol, 10 mM NaF, and 10 mM NaPP, supplemented with 4% protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN), and cleared by centrifugation. Protein concentration was determined by the Bradford assay (Bio-Rad, Hercules, CA). Equal protein samples (30-80 µg) were separated on SDS-PAGE gels and electro-transferred onto Hybond-P polyvinylidene difluoride filters (Amersham Life Science, Arlington Heights, IL). The filters were then probed with the specific primary antibodies, and the immune-reactive bands visualized with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG, goat anti-rabbit IgG, or donkey anti-sheep IgG (H+L) (Bio-Rad, Hercules, CA), as appropriate, using an ECL Plus Western Blotting Detection System (Amersham Life Science, Arlington Heights, IL), and quantified by densitometric analysis using the Versadoc imaging system (Bio-Rad, Hercules, CA). 
Antibodies
qRT-PCR
Total RNA was isolated from HUVEC using the RNeasy Mini Kit (Qiagen, Hilden, Germany). Genomic DNA contamination was eliminated by DNase digestion (Qiagen, Hilden, Germany), and cDNA was obtained using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Weiterstadt, Germany). Primers for E-Selectin, p66
Shc , and β-actin were designed using Primer Express 3.0 (Applied Biosystems, Weiterstadt, Germany). Primer sequences were designed as follows: E-Selectin_For: 5'-GAAGGATGGACGCTCAATGG-3' and E-Selectin_Rev: 5'-TGGACTCAGTGGGAGCTTCAC-3'; p66
Shc _For: 5'-CCCCCAAGCCCAAGTACAA-3'; p66 Shc _Rev: 5'-GACCCAGAAGCCCCTTCCT-3'; β-actin_For: 5'-TGGATCAGCAAGCAGGAGTATG-3' and β-actin_Rev: 5'-GCATTTGCGGTGGACGAT-3'. The PCR reactions were carried out in an ABI PRISM 7500 System (Applied Biosystems, Weiterstadt, Germany). The PCR reactions were carried out under the following conditions: 50°C for 2 min, 95°C for 10 min, 40 cycles at 95°C for 15 sec, and 60°C for 1 min. Relative gene expression levels were determined by analyzing the changes in SYBR green fluorescence during qRT-PCR using the ΔΔCt method. To confirm amplification of specific transcripts, melting curve profiles were produced at the end of each reaction. The mRNA level of each gene was normalized using β-actin as internal control. 
Immunofluorescence analyses
ROS analyses
ROS production was detected through the evaluation of dihydroethidium (DHE) oxidation using a Jasco FP6200 spectrofluorimeter (Jasco, Easton, MD). Cells were incubated with 20 mM DHE for 0.5 h at 37°C in a serum-free medium in the dark, then washed with PBS, collected by trypsinization and resuspended in assay buffer (100 mM potassium phosphate, pH 7.4, 2 mM MgCl 2 ), using an aliquot for protein determination. The fluorescence increase (480 nm excitation and 567 nm emission wavelength) caused by the ROSdependent oxidation of DHE was expressed as arbitrary units normalized by cell protein content. Shc , were incubated with 50 ng/ml TNFα for 4 h or left untreated. FITC-dextran was added to the upper chamber for 20 min. The amount of FITC-dextran diffused into the bottom chamber was determined by measuring the fluorescence at 485 nm and 535 nm of excitation and emission, respectively, and expressed as arbitrary units.
Leukocyte transmigration test
Statistical analysis
Data are presented as mean ±SE of at least three independent experiments, unless differently specified in the Figure legend, 
Results
TNFα action and signaling in HUVEC
Leukocyte transmigration through the endothelial monolayer, which represents a marker of endothelial activation, was significantly increased after exposure of HUVEC to TNFα for 1 h (P<0.05 vs. basal; Figure 1A ). E-Selectin mRNA levels, measured by qRT-PCR, were also significantly increased by TNFα, reaching a peak at 4 h (P<0.05 vs. basal; Figure 1B ). In addition, E-Selectin protein levels were time-dependently increased by TNFα, and persisted elevated up to 24 h (P<0.05 vs. basal; Figure 1C ). Selective inhibition of E-Selectin expression following transfection of a specific siRNA ( Figure  S1A ) resulted in significantly decreased leukocyte transmigration (P<0.05 vs. control; Figure 1D ), indicating a major role of this adhesion molecule in endothelial activation.
Exposure to TNFα induced the phosphorylation of the stress kinases JNK-1 and JNK-2 in HUVEC, with a significant activation peak at 0.5 h (P<0.05 vs. untreated cells; Figure  S1B ). Similarly, ERK-1/2 was also rapidly activated upon exposure to TNFα. ERK-1/2 phosphorylation increased approximately 2-fold both 0.5 h and 1 h following stimulation with TNFα (P<0.05 vs. basal), and then gradually declined ( Figure S1C ). To investigate the role of JNK in TNFα-induced E-Selectin expression, HUVEC were pretreated with SP600125, prior to challenge with TNFα. Under these conditions, the TNFα-induced increase in E-Selectin mRNA levels was reduced by 85% (P<0.05 vs. TNFα-treated cells; Figure 1E ). By contrast, preincubation with the MEK inhibitor PD98059 (30 µM) did not alter the effect of TNFα on E-Selectin mRNA ( Figure 1E ). Similar results were obtained also using higher concentrations of PD98059 (50 µM, data not shown). The TNFα-induced increase in E-Selectin protein levels was also inhibited by the JNK inhibitors SP600125 and the JNKi peptide and not by the MEK inhibitor, respectively ( Figure S2 , A-D). Altogether, these findings indicate that TNFα stimulates the increase of E-Selectin gene expression via JNK but not ERK signaling in HUVEC.
Effects of TNFα on p66
Shc activation in HUVEC
To assess the potential involvement of p66
Shc in TNFα signaling, HUVEC were exposed to increasing doses of TNFα (0-50 ng/ml), and p66
Shc phosphorylation on Ser 36 was evaluated. Exposure to TNFα induced a dose-dependent increase in p66 Shc Ser-phosphorylation, which was augmented 2-fold with 50 ng/ml of TNFα (P<0.05 vs. untreated cells; Figure 2A ). Time-course analysis of p66
Shc phosphorylation in response to TNFα showed a 3-fold significant increase that occurred after 0.5 h (P<0.05 vs. basal; Figure 2B ). The contribution of JNK and ERK activation to the TNFα-induced Ser-phosphorylation of p66
Shc was then studied using the SP600125 and PD98059 inhibitors, respectively. When cells were pretreated with SP600125, the TNFα effect on p66
Shc Serphosphorylation was greatly reduced (P<0.05 vs. TNFα-treated cells; Figure 2C ). By contrast, treatment with PD98059 did not affect the ability of TNFα to induce p66
Shc phosphorylation on Ser 36 ( Figure 2D ). When cells were pretreated with the p38 MAPK inhibitor SB203580 or the PKC-β inhibitor LY333531, respectively, the TNFα effect on p66
Shc Ser-phosphorylation was partially impaired (P<0.05 vs. controls; Figure S3A and B). Thus, these results suggests that JNK, and partially p38 and PKC-β, but not ERK, are involved in the ability of TNFα to rapidly stimulate p66
Shc phosphorylation on Ser 36 in HUVEC.
Effects of p66
Shc overexpression on TNFα action in HUVEC
To investigate the role of p66
Shc in TNFα signaling and action, HUVEC with adenovirus-mediated overexpression of p66 Shc (HUVEC/p66 Shc ) were obtained. HUVEC/p66 Shc showed normal cellular morphology, similarly to control cells ( Figure  3A ). Moreover, in the context of augmented p66
Shc expression and phosphorylation ( Figure S4 , A-C), the pattern of JNK and ERK activation was similar in HUVEC/p66
Shc and control cells, since JNK-1/2 phosphorylation peaked at 0.5 h (P<0.05 vs. untreated cells; Figure S5A ), and ERK-1/2 phosphorylation was increased at 0.5 h and 1 h following exposure to TNFα (P<0.05 vs. untreated cells; Figure S5B ). Increased p66
Shc expression and phosphorylation also did not apparently affect other signaling pathways, such as that involving NF-κB. In both HUVEC/wt and HUVEC/mock, NF-κB was found to be localized in the cytoplasm in the basal state and was translocated to the nucleus following TNFα stimulation ( Figure S6 , A and B), and similar results were obtained in HUVEC/p66 Shc ( Figure S6D ). In parallel, Ser 32 -IκBα phosphorylation was induced by TNFα, but not affected by p66
Shc overexpression ( Figure S6E ). Therefore, increased p66 Shc expression and phosphorylation was apparently not linked to or did not interfere with the ERK or NF- Figure 1 . Effects of TNFα on endothelial activation in HUVEC. Cells were incubated with 50 ng/ml TNFα for the indicated times or left untreated. A. Leukocyte transmigration test. HL-60 cells were added to HUVEC/wt, stimulated with 50 ng/ml TNFα for 4 h, and left to migrate for 18 h at 37°C. Migrated cells were stained and measured by OD at 450 nm. Data represents the mean of triplicates from two independent experiments, and are normalized to control. *P<0.05 vs. no TNFα. B. TNFα regulation of E-Selectin mRNA levels. E-Selectin mRNA levels were evaluated by qRT-PCR, and normalized using β-actin as internal control. C. TNFα regulation of E-Selectin protein levels. E-Selectin protein levels were evaluated by immunoblotting, using GAPDH as internal control. D. Leukocyte transmigration test. HL-60 cells were added to control HUVEC (treated with negative siRNA) and HUVEC treated with E-Selectin siRNA#1 (50 nM) or siRNA#2 (100 nM) for 48 h, and left to migrate for 18 h at 37°C. Studies were carried out under basal conditions. Migrated cells were stained and measured by OD at 450 nm. Data represents the mean of triplicates of one experiment and are normalized to control. *P<0.05 vs. negative siRNA. E. Effects of SP600125 (left) and PD98059 (right) on TNFα-induced E-Selectin mRNA expression. Cells were pre-treated with 30 mM JNK or MEK inhibitor, respectively, for 2 h and then exposed 50 ng/ml TNFα for the indicated times (untreated cells, black; inhibitor-treated cells, grey; DMSO-treated cells, light grey). E-Selectin mRNA levels were evaluated by qRT-PCR, using β-actin as internal control. *P<0.05 vs. basal; # P<0.05 vs. TNFα-stimulated cells. Figure 3B ) and E-Selectin mRNA levels were moderately higher than in control cells (P<0.05 vs. HUVEC/wt and HUVEC/mock; Figure 3C , inset). However, after treatment with 50 ng/ml TNFα for 1 h, both leukocyte transmigration and E-Selectin mRNA were induced several-fold (P<0.01 vs. untreated HUVEC/p66 Shc ; Figure 3 , B and C), and markedly higher in HUVEC/p66
Shc compared with control cells (P<0.05 vs. HUVEC/wt and HUVEC/mock; Figure 3 , B and C). ESelectin protein was also found to be increased in HUVEC/ p66
Shc compared to control cells after exposure to TNFα (P<0.05 vs. HUVEC/mock after TNFα for 1 h; Figure S5C ).
Treatment of HUVEC/p66
Shc with SP600125 tended to reduce basal E-Selectin gene expression (P=0.081 vs. untreated HUVEC/p66
Shc ; Figure 3C , inset), and significantly reduced TNFα-stimulated E-Selectin mRNA (P<0.05 vs. HUVEC/p66 Shc cells treated with TNFα alone; Figure 3C ), and this was paralleled by decreased p66
Shc Ser 36 phosphorylation levels both under basal conditions and following TNFα stimulation (P<0.05 vs. controls, Figure 4A ). In contrast, preincubation of HUVEC/p66 Shc with PD98059 had no effect on p66 Shc phosphorylation and did not modify basal or TNFα-induced ESelectin mRNA levels (data not shown).
The effects of p66 Shc overexpression on Vascular Endothelial (VE)-cadherin and β-catenin expression were investigated next, to explore the potential involvement of p66 Shc in regulating vascular permeability. Cells with increased p66
Shc expression showed downregulation of VE-cadherin ( Figure 5 , A and C) and increased expression of β-catenin ( Figure 5 , B, D and E) compared to controls (HUVEC/mock). Since the VE-cadherin/ β-catenin complex modulates endothelial permeability, a FITCdextran-based assay was used to evaluate the permeability of HUVEC monolayers. Leakage of the FITC-dextran marker was found to be increased in HUVEC/p66
Shc compared to control HUVEC (P<0.05; Figure 5F ). Exposure to 50 ng/ml TNFα for 4 h resulted in reduced VE-cadherin and increased β-catenin expression ( Figure 5, C-E) , and greater FITC-dextran leakage in control HUVEC and even more so in HUVEC/p66 Shc (P<0.05 vs. control HUVEC; Figure 5F ). Hence, these data show that p66
Shc , in addition to regulating leukocyte transmigration, mediates also changes in endothelial cell permeability, through modifications in the VE-cadherin/β-catenin complex.
Effects of p66
Shc silencing on TNFα-induced endothelial activation
To confirm the involvement of p66
Shc in the effects of TNFα on endothelial activation, p66
Shc gene expression was silenced using two independent siRNAs. Transfection of HUVEC with these siRNAs resulted in 40% to 70% reductions, respectively, of p66
Shc mRNA levels compared to control (P<0.05; Figure  S7A ). p66
Shc protein levels and Ser 36 phosphorylation were also significantly reduced with both siRNAs (P<0.05; Figure 6A ).
Knockdown of p66
Shc resulted in a significant inhibition of leukocyte transmigration across the HUVEC monolayer (P<0.05; Figure 6B ), and this was associated with 80% and 60% decreases of E-Selectin mRNA levels under basal conditions and following stimulation with TNFα for 1 h, respectively (P<0.05; Figure 6C ). TNFα-induced E-Selectin protein expression was regulated through the JNK, but not ERK, pathway also in siRNA-treated HUVEC ( Figure S7 , B and C). These results indicate that p66
Shc plays an important role in leukocyte transmigration mediated by changes in E-Selectin expression in HUVEC.
Involvement of oxidative stress in p66
Shc signaling To investigate whether p66
Shc regulates E-Selectin expression by modulating oxidative stress, intracellular reactive oxygen species (ROS) levels were measured in the experimental cells. In HUVEC/p66
Shc , ROS levels were increased 8-fold compared to controls (P<0.05; Figure 7A ). Stimulation with TNFα induced a weak but significant increase of ROS levels in control HUVEC and HUVEC/p66
Shc (P<0.05 vs. basal; Figure 7A ), and pretreatment with SP600125 blocked this response (P<0.05 vs. cells treated with TNFα alone; Figure  7A ). Furthermore, pretreatment with the antioxidant N-acetylcysteine (NAC) inhibited the increase in E-Selectin gene and protein expression induced by TNFα ( Figure 7C ), but also reduced p66
Shc phosphorylation on Ser 36 ( Figure 7B ). In addition, coincubation of cells with TNFα and various ROS inhibitors, including the NADPH oxidase inhibitor VAS2870, and the complex I inhibitors rotenone and thenoyltrifluoroacetone (TTFA), respectively, resulted in reduced p66
Shc Ser 36 phosphorylation induced by TNFα ( Figure  7D ). These results suggest that the involvement of p66
Shc in the TNFα-induced increase in E-Selectin expression is both dependent on and acting through an increase in intracellular ROS levels. Shc by approximately 2-3 fold ( Figure 4A) ; nevertheless, as expected, basal and TNFα-stimulated p66
Role of
Shc phosphorylation was similar in HUVEC/ p66
Shc Ala 36 and in control cells, and was reduced compared to HUVEC/p66 Shc ( Figure S4 , A-C; Figure 4A ). HUVEC morphology was not altered following overexpression of the mutant p66 Shc ( Figure S4D ). Importantly, HUVEC/p66 Shc Ala 36 showed a minimal increase in leukocyte transmigration compared to HUVEC/mock, but a markedly lower response compared to HUVEC/p66 Shc with total impairment of the TNFα effect ( Figure 4B) Figure 5 ). Therefore, p66 Shc phosphorylation on Ser 36 appears to be important for the ability of this protein to mediate the effects of TNFα on E-Selectin gene expression and function in HUVEC, and this signaling event is apparently dependent upon JNK activation and ROS generation ( Figure 4D ).
Discussion
Endothelial dysfunction is a systemic disorder and a key variable in the pathogenesis of atherosclerosis and its complications. Expression of adhesion molecules, leading to leukocyte rolling and diapedesis, represents one of the earliest events in the atherogenic cascade. Hence, reverting the biological processes leading to endothelial activation may be an attractive target in the effort to optimize individualized therapeutic strategies to reduce cardiovascular morbidity and mortality [34] . The p66
Shc protein has been shown to control cellular responses to oxidative stress, being involved in atherosclerosis in animal models [26, 35, 36] . Deletion of the p66 Shc gene protects against age-related endothelial dysfunction [37] and reduces systemic and tissue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed a high-fat diet [26] . In this study, we provide further insight into the cellular mechanisms mediating endothelial dysfunction, by showing that the stress-sensor protein p66
Shc is implicated in TNFα action in HUVEC, a well-defined cellular model of the human endothelium.
Accumulating evidence suggests that the pro-inflammatory cytokine TNFα plays an important role in the disruption of vascular responses [38] . TNFα stimulates the expression of endothelial cell genes, including E-Selectin, which may promote atherosclerosis via leukocyte recruitment [10] . In this study, challenge of HUVEC with TNFα resulted in increased ESelectin expression, in line with similar results obtained in other endothelial cell systems [39] . This response occurred via the activation of the stress-kinase JNK [40] , whereas ERK was apparently not involved.
Phosphorylation of p66 Shc on Ser 36 has been shown to mediate cellular aging, damage, and apoptosis, and to be induced by oxidative stress [41] . We found that stimulation of HUVEC with TNFα induced a 2-to 3-fold increase in p66 Shc phosphorylation on Ser 36 ( Figure 2, A and B) , which was almost completely blocked by pretreatment of cells with the specific JNK inhibitor (Figure 2 , C and D) and only partially reduced by pretreatment of cells with the p38 inhibitor ( Figure S3A ), in line with previous results obtained in bovine aortic endothelial cells exposed to H 2 O 2 [41] and in HUVEC treated with the Vascular Endothelial Growth Factor [42] . Specific isoforms of the protein kinase C (PKC) family have also been proposed as mediators of ROS triggered stress signals. Indeed, oxidative stress has been shown to activate the PKC-β isoform, leading to Ser 36 -phosphorylation and mitochondrial translocation of p66
Shc , and increased cell apoptosis [43] . In this study, the specific PKC-β inhibitor LY333531 reduced TNFα-induced phosphorylation of p66
Shc on Ser 36 ( Figure S3B ). Interestingly, p66 Shc induces mitochondrial H 2 O 2 production, resulting in further augmentation of intracellular H 2 O 2 levels and PKC-β activation, in a sort of self-triggered control loop [43] . In HUVEC, the PKC-β inhibitor LY333531 reduced AGEs-induced macrophage adhesion to endothelial cells, thus relieving the local inflammation [44] . It has also been previously demonstrated that the inhibition of PKC-β prevents the activation of the JNKp66
Shc proatherogenic pathway in human aortic endothelial cells [45] , in line with the results of our study.
The effect of TNFα on p66 Shc phosphorylation on Ser 36 was tightly associated with the ability of this cytokine to induce ESelectin expression and leukocyte transmigration. Cells with selective overexpression of p66
Shc and enhanced p66
Shc phosphorylation on Ser 36 showed increased E-Selectin expression and leukocyte transmigration, under basal conditions, and more so after stimulation with TNFα ( Figure 3 , B and C). A similar effect was observed when we studied endothelial permeability, which appeared to be increased in p66
Shc -overexpressing cells, and further increased in response to TNFα ( Figure 5F ). This was associated with reduced VEcadherin and increased β-catenin protein levels, respectively ( Figure 5, A-E) . Changes in VE-cadherin levels may significantly affect vascular permeability [16, 22, 46] , and disruption of the adherent junctions at the level of VE-cadherin and β-catenin is an important mechanism leading to microvascular hyperpermeability [20] . Indeed, the increased degradation of VE-cadherin may be due to the disruption of cadherin-catenin complexes [47] . Interestingly, enhanced endothelial cell permeability associated with increased β-catenin expression and disruption of the VE-cadherin/β-catenin complexes, as found in HUVEC overexpressing wild-type p66 Shc ( Figure 5 ) in this study, has been also observed in HUVEC treated with LPS and Ucn-1 [22] .
Thus, p66 Shc appears to enhance the cellular sensitivity to the effects of TNFα, similarly to the increased susceptibility to toxic damage and apoptosis observed in other cellular models of p66 Shc overexpression [48] . Conversely, deletion of p66 Shc conferred protection from oxidative injury and apoptosis in both cellular systems in vitro and experimental animals in vivo [26, 35] . In parallel with these observations, siRNA-mediated p66 Shc gene silencing resulted in marked reduction of ESelectin expression and leukocyte transmigration both under basal conditions and after TNFα stimulation ( Figure 6 , B and C). The role of p66
Shc phosphorylation on Ser 36 in this response was established by overexpressing a phosphorylation-defective p66
Shc mutant protein in HUVEC, which raised total p66
Shc protein levels to those found in the HUVEC overexpressing the wild-type p66 Shc ( Figure S7 , A-C; Figure 4A ), but failed to enhance E-Selectin expression or leukocyte transmigration as that observed in HUVEC/p66
Shc ( Figure 4 , B and C). In multiple experimental models, p66
Shc -dependent biological responses appear to be largely inhibited when Ser 36 is mutated, even though the extent of inhibition may vary depending on the cell type and specific amino acid substitution (i.e., Ser-to-Ala vs. Ser-to-Asp) [49] . Our results confirm previous observations on the critical role of Ser 36 phosphorylation of p66 Shc for induction of the apoptosis cascade in cells exposed to oxidative stress [24] . Interestingly, ROS production was associated with activation of the JNK-p66 Shc pathway ( Figure 7A ), and pretreatment with the antioxidant NAC resulted in a significant decrease in TNFα-induced p66
Shc phosphorylation and ESelectin expression ( Figure 7B ). The mitochondrial respiratory chain is considered the main intracellular source of ROS; indeed, the NADPH oxidase complex has been involved in endothelial dysfunction [50] and Ser 36 phosphorylation of p66 Shc in normal fibroblasts [51] . It was previously demonstrated that rotenone and TTFA (10 µM), which inhibit electron transfer to ubiquinone, significantly decreased ROS generation in HUVEC [52] . A decrease in ROS production has been reported also in HUVEC treated with the flavo-enzymes inhibitor diphenylene iodinium (10 µM) [52] and the NADPH oxidase inhibitor VAS2870 (5 µM) after incubation with TNFα and oxidized lowdensity lipoprotein, respectively [53, 54] . In contrast, antimycin A (AA, 10 µM), a blocker of ubisemiquinone, increased ROS generation [52] . In this study, Ser 36 phosphorylation of p66
Shc was significantly decreased when cells were exposed to the NADPH oxidase inhibitor VAS2810, and to the complex I inhibitors rotenone and TTFA, suggesting a role for both cytosolic and mitochondrial ROS in p66 Shc activation in endothelial cells ( Figure 7D ). Hence, E-Selectin expression appears to be, at least in part, under ROS control ( Figure 7C ), in line with previous reports [55] . In HUVEC/p66
Shc , phosphorylation of p66 Shc on Ser 36 was found to be significantly increased also in the absence of TNFα stimulation ( Figure 4A ), and this was associated with some enhancement of basal ESelectin mRNA levels ( Figure 3C ). This "constitutive" p66 Shc Ser phosphorylation was partly reduced when HUVEC/p66 Shc were preincubated with the specific JNK inhibitor ( Figure 4A ), even though we could not document changes in JNK phosphorylation by immunoblotting ( Figure S5A ). This phenomenon could potentially result from the effects of augmenting p66
Shc protein levels in the presence of a low yet effective level of basal JNK activity.
The downstream targets of p66 Shc , potentially involved in the regulation of E-Selectin gene expression in HUVEC, are still poorly characterized. p66
Shc has been shown to phosphorylate and inactivate FOXO3a, which is involved in the modulation of antioxidant defenses in cardiomyocytes [56] . However, there is no evidence of FOXO3a expression in endothelial cells, or of any FOXO3a-mediated transcriptional modulation of ESelectin. p66
Shc has also been shown to regulate the transcriptional regulator Kruppel-like factor (KLF2), since knockdown of p66
Shc in endothelial cells induced mRNA expression of KLF2 and of its target gene thrombomodulin [57] . In addition, overexpression of KLF2 potently inhibited the induction of VCAM-1 and E-Selectin in response to proinflammatory cytokines, including TNFα [58] , suggesting KLF2 as a likely candidate mediating the effects of p66
Shc on ESelectin. However, we found that selective overexpression or knockdown of p66
Shc did not modify KLF2 mRNA levels in HUVEC (data not shown).
In animal models, the p66 Shc protein has been shown to be involved in the cellular events leading to atherosclerosis.
Overexpression of the p66
Shc gene has been shown to reduce nitric oxide generation in endothelial cells, whereas downregulation or deletion of the p66
Shc gene improved the impaired endothelial cell-dependent vasodilation [36] . In humans, the expression of p66
Shc has been evaluated in circulating monocytes, which are key contributors to the vascular damage. The levels of p66 Shc in monocytes were significantly increased in patients with type 2 diabetes compared with controls, and were correlated to total plasma 8-isoprostane, a marker of oxidative stress [28] . More recently, p66
Shc was found to be increased in monocytes from patients with coronary artery disease, with a direct correlation between p66
Shc levels and the number of diseased vessels [59] . In this study, we provide evidence that p66
Shc , through its regulatory Ser 36 phosphorylation, lies downstream of JNK in the TNFα/JNK signaling pathway that controls E-Selectin gene expression in human endothelial cells ( Figure 4D) . Interestingly, modulation of p66
Shc expression appears to affect the ability of endothelial cells to induce leukocyte transmigration, a process which involves an E-Selectindependent mechanism [60] (Figure 1D phosphorylation and E-Selectin protein expression. HUVEC were preincubated with 10 mg/ml JNKi peptide for the indicated times, and then exposed to 50 ng/ml TNFα for 1 h. E-Selectin protein levels were evaluated by immunoblotting, using Shc protein expression as loading control. c-Jun Ser 63 phosphorylation was evaluated as a readout for the activity of the inhibitor, using c-Jun protein content as loading control. (TIF) Figure S3 . Shc (siRNA#1 and siRNA#2). Cells were lysed 48 h or 72 h later, and p66
Shc mRNA levels were measured by qPCR. wt, wild-type cells; Lipo, cells treated with Lipofectamine™ only; Negative siRNA, cells transfected with a negative control siRNA. B and C. Effects of siRNA-mediated knockdown of p66
Shc on E-Selectin protein expression under basal conditions and following TNFα stimulation in HUVEC pretreated with SP600125 (B) and PD98059 (C). HUVEC were transfected for 72 h with 100 nM siRNA#1 and or negative control siRNA, and preincubated with SP600125 or PD98059 (30 mM, 2h), using DMSO as control, before treatment with 50 ng/ml TNFα for 1 h. Lysates were analyzed by immnoblotting, using p52
Shc and p46 Shc as controls. Black bars, cells transfected with a negative control siRNA; white bars, cells transfected with 100 nM siRNA#1. (TIF)
